Chemical compounds

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes compounds of formula (I) wherein: R1 means C1-6alkyl or C3-6cycloalkyl; wherein R1 may be optionally carbon-substituted by one or more R6; R2 means hydrogen; R3 and R4 are carbon substitutes, and each is independently specified in carboxy, carbamoyl, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, N-(C1-6alkoxy)carbamoyl, phenyl-R9 - or heterocyclyl-R10-; wherein R3 and R4 may be independently carbon-substituted by one or more R11; and wherein provided said heterocyclyl contains -NH - residue, then nitrogen may be optionally substituted by a group specified in R12; m has the value of 0, 1 or 2; wherein the values R3 may be equal or different; p has the value of 0, 1 or 2; wherein the values R4 may be equal or different; the ring A means nitrogen-containing 5- or 6-member heterocyclic group; wherein drawn nitrogen represents = N- and is found in an ortho-position to R1R2NC(O)NH group in formula (I); the ring B means phenyl or heterocyclyl; wherein provided said heterocyclyl contains -NH- residue, then nitrogen may be optionally substituted by a group specified in R14; R5 is specified in hydroxy, C1-6alkoxy or -N(R15)(R16); R6 and R11 are carbon substitutes and each is independently specified in halo, C1-6alkyl or C1-6alkoxy; R15 and R16 are independently specified in hydrogen, C1-6alkyl, C1-6alkoxy, cyclopropyl or cyclopentyl; R12 and R14 mean C1-6alkyl; wherein R14 may be optionally carbon specified by one or more R23; R9 and R10 mean a direct link; and R23 means halo or methoxy; wherein said heterocyclyl means pyridine, imidazole, triazole, thiazole, benzothiazole, imodazolepyridine, dihydroquinoline or thiadiazole, or its pharmaceutically acceptable salt; provided said compound represents other than ethyl ester of 5-[2-[[(ethylamino)carbonyl]amino]pyridin-4-yl]-4-methyl-4H-1,2,4-triazole-3-carboxylic acid or their pharmaceutically acceptable salts. There are also described pharmaceutical compositions on the basis of said compounds, a method for bacterial DNA-hydrase and/or bacterial topoisomerase IV inhibition in a homoiothermal animal, as well as a method of treating an infection in a homoiothermal animal.

EFFECT: there are prepared and described new compounds showing antibacterial activity.

24 cl, 165 ex

 

The text descriptions are given in facsimile form.

1. The compound of formula (I)

where
R1means1-6alkyl or C3-6cycloalkyl; where R1may be optionally substituted on carbon by one or more R6;
R2means hydrogen;
R3and R4are substituents on carbon are each independently selected from carboxy, carbamoyl, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanolamine, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, N-(C1-6alkoxy)carbamoyl, phenyl-R9or heterocyclyl-R10-; where R3and R4independently from each other may be optionally substituted on carbon by one or more R11; and where if the mentioned heterocyclyl contains an-NH - rest, that nitrogen may be optionally substituted by a group selected from R12;
m is 0, 1 or 2; where the values of R3may be the same or different;
p is 0, 1 or 2; where the values of R4may be the same or different;
ring a represents nitrogen-containing 5 - or 6-membered heterocyclic group; where drawn nitrogen is a =N and is orthopaedie to R1R2NC(O)NH-group in the formula (I);
ring means phenyl or heterocyclyl; where if the mentioned heterocyclyl contains an-NH - rest, that nitrogen may be optionally substituted by a group selected from R 14;
R5selected from hydroxy, C1-6alkoxy, or-N(R15)(R16);
R6and R11are substituents on carbon are each independently selected from halo, C1-6the alkyl or C1-6alkoxy;
R15and R16independently selected from hydrogen, C1-6of alkyl, C1-6alkoxy, cyclopropyl or cyclopentyl;
R12and R14mean1-6alkyl; R14may be optionally substituted on carbon by one or more R23;
R9and R10mean direct communication and
R23means halo, or methoxy;
where mentioned heterocyclyl means pyridine, imidazole, triazole, thiazole, benzothiazole, imidazopyridine, dihydroquinoline or thiadiazole, or its pharmaceutically acceptable salt;
provided that the compound is not a difficult ethyl ester 5-[2-[[(ethylamino)carbonyl]amino]pyridine-4-yl]-4-methyl-4H-1,2,4-triazole-3-carboxylic acid.

2. The compound according to claim 1, where the ring And are selected from the group consisting of pyridyl, pyrimidinyl and thiazolyl.

3. The compound according to claim 1, where the said compound of formula (I) is a compound of formula (XIV)

or its pharmaceutically acceptable salt.

4. The compound according to claim 1, where the said compound of formula (I) is a compound of formula (XV)

or its pharmaceutically acceptable salt.

5. The compound according to claim 1, where the said compound of formula (I) is a compound of formula (XVI)

or its pharmaceutically acceptable salt.

6. The compound according to claim 1, where the said compound of formula (I) is a compound of formula (XVII)

or its pharmaceutically acceptable salt, where R25means hydrogen or R3.

7. The compound according to any one of claims 1 to 6, where a ring selected from the group consisting of thiazolyl, pyridyl, 1,3-benzothiazolyl, phenyl, imidazo[1,2-a]pyridinyl, 4-oxo-1H-chinoline and 2-oxo-1H-pyridyl.

8. The connection according to claim 7, where m takes on the value 0.

9. The connection according to claim 7, where m takes on the value 1.

10. The connection according to claim 9, where R3selected from the group consisting of pyridyl, phenyl and thiazolyl where pyridyl, phenyl or thiazolyl may be optionally substituted on one or more carbon atoms by one or more R11.

11. The connection according to claim 7, where m means 2.

12. Connection to item 11, where R3in each case, independently selected from the group consisting of pyridyl, phenyl and thiazolyl where pyridyl, phenyl or thiazolyl may be optionally substituted on one or more carbon atoms by one or more R11.

13. The connection according to claim 7, where p is inimal 0.

14. The connection according to claim 7, where p takes the value 1.

15. The connection according to claim 7, where R takes the value of 2.

16. The compound according to claim 1, where the said compound is a compound of formula (XVIII)

or its pharmaceutically acceptable salt, where:
X is CH or N; and
R29mean 6-membered aryl or 5 - or 6-membered heteroaryl, where the aryl or heteroaryl optionally substituted by one or more carbon atoms by one or more R11; and where, if heteroaryl contains residue-NH-, the hydrogen may be optionally substituted by a group selected from R

17. Connection P16, where the ring selected from the group consisting of phenyl, pyridyl and thiazolyl.

18. Connection P16, where R29selected from the group consisting of pyridyl, thiazolyl and phenyl, where pyridyl, thiazolyl or phenyl may be optionally substituted on one or more carbon atoms by one or more R11.

19. Connection p where the above-mentioned compound is a compound of formula (XIX)

or its pharmaceutically acceptable salt.

20. The connection according to claim 19, where the said compound is a compound of formula (XX)

or its pharmaceutically acceptable salt.

21. The compound or its pharmaceutically who ramlila salt, selected from the group consisting of:
Methyl 2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylate;
Ethyl 2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-4-carboxylate;
Ethyl 6'-{[(ethylamino)carbonyl]amino}-3,3'-bipyridine-5-carboxylate;
Ethyl 2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-benzothiazole-7-carboxylate;
Methyl 6'-{[(ethylamino)carbonyl]amino}-2,3'-bipyridine-5-carboxylate;
Methyl 3-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)benzoate;
Methyl 4-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)benzoate;
Isopropyl 2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-4-[(methylamino)-carbonyl]-1,3-thiazole-5-carboxylate;
Ethyl 4-[(cyclopropylamino)-carbonyl]-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylate;
Ethyl 4-[(butylamino)-carbonyl]-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylate;
Methyl 4-acetyl-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylate;
Methyl 6-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)imidazo [1,2-a]pyridine-2-carboxylate;
Methyl 3-(2-{[(ethylamino)carbonyl]amino}pyrimidine-5-yl)benzoate;
Methyl 2-(2-{[(ethylamino)carbonyl]amino}pyrimidine-5-yl)-1,3-thiazole-5-carboxylate;
Ethyl 3-(6-{[(ethylamino)carbonyl]amino}pyridin-2-yl)benzoate;
Ethyl 4-(6-{[(ethylamino)carbonyl]amino}pyridin-2-yl)benzoate;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylic Ki the lot;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-4-carboxylic acid;
6'-{[(Ethylamino)carbonyl]amino}-3,3'-bipyridine-5-carboxylic acid;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-benzothiazole-7-carboxylic acid;
6'-{[(Ethylamino)carbonyl]amino}-2,3'-bipyridine-5-carboxylic acid;
3-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)benzoic acid;
4-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)benzoic acid;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-4-[(methylamino)carbonyl]-1,3-thiazole-5-carboxylic acid;
4-[(Cyclopropylamino)-carbonyl]-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylic acid;
4-[(Butylamino)carbonyl]-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylic acid;
4-Acetyl-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylic acid;
6-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid;
3-(2-{[(Ethylamino)carbonyl]amino}pyrimidine-5-yl)benzoic acid;
2-(2-{[(Ethylamino)carbonyl]amino}pyrimidine-5-yl)-1,3-thiazole-5-carboxylic acid;
3-(6-{[(Ethylamino)carbonyl]amino}pyridin-2-yl)benzoic acid;
4-(6-{[(Ethylamino)carbonyl]amino}pyridin-2-yl)benzoic acid;
4-(2-{[(Ethylamino)carbonyl]amino}-1,3-thiazol-4-yl)benzoic acid;
2-(6-{[(Ethylamino)carbonyl]-amino}pyridine-3-yl)-N-methoxy-1,3-thiazole-5-carboxamide; N-Cyclopropyl-2-(6-{[(ethylamino)carbonyl]-amino}pyridine-3-yl)-N5-methoxy-1,3-thiazole-4,5-dicarboxamide;
N4-Butyl-2-{6-{[(ethylamino)carbonyl]-amino}pyridine-3-yl)-N-methoxy-1,3-thiazole-4,5-dicarboxamide;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxamide;
N4-Cyclopropyl-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-4,5-dicarboxamide;
N4-Butyl-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-4,5-dicarboxamide;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-benzothiazole-7-carboxamide Methyl 4-(2-{[(ethylamino)carbonyl]amino}-1,3-thiazol-4-yl)benzoate;
Ethyl 6-(6-(3-ethylurea)pyridine-3-yl)-1-(2-methoxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate;
Ethyl 1-butyl-6-(6-(3-ethylurea)pyridine-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate;
Ethyl 6-(6-(3-ethylurea)pyridine-3-yl)-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate;
Ethyl 1-(2,2-dottorati)-6-(6-(3-ethylurea)pyridine-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate;
6-(6-(3-Ethylurea)pyridine-3-yl)-1-(2-methoxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;
1-Butyl-6-(6-(3-ethylurea)pyridine-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;
6-(6-(3-Ethylurea)pyridine-3-yl)-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;
1-(2,2-Dottorati)-6-(6-(3-ethylurea)pyridine-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;
Methyl 5-(6-(3-this is ureido)pyridine-3-yl)-2-oxo-1,2-dihydropyridines-3-carboxylate;
5-(6-(3-Ethylurea)pyridine-3-yl)-2-oxo-1,2-dihydropyridines-3-carboxylic acid;
Ethyl 4-dimethylcarbamoyl-2-[6-(3-ethylurea)-pyridine-3-yl]-thiazole-5-carboxylate;
4-[(dimethylamino)carbonyl]-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylic acid;
N5-Ethyl-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-N4N4-dimethyl-1,3-thiazole-4,5-dicarboxamide;
4-Dimethylamide, 5-propelled 2-[6-(3-ethylurea)-pyridine-3-yl]-thiazole-4,5-dicarboxylic acid;
4-Dimethylamide, 5-isopropylamino 2-[6-(3-ethylurea)-pyridine-3-yl]-thiazole-4,5-dicarboxylic acid;
bis-Dimethylamide 2-[6-(3-ethylurea)-pyridine-3-yl]-thiazole-4,5-dicarboxylic acid;
5-Cyclopentene, 4-dimethylamide 2-[6-(3-ethylurea)-pyridine-3-yl]-thiazole-4,5-dicarboxylic acid;
Ethyl 4-ethylcarboxyl-2-[6-(3-ethylurea)-pyridine-3-yl]-thiazole-5-carboxylate;
4-Ethylcarboxyl-2-[6-(3-ethylurea)-pyridine-3-yl]-thiazole-5-carboxylic acid;
5-Dimethylamide, 4-ethylamide 2-[6-(3-ethylurea)-pyridine-3-yl]-thiazole-4,5-dicarboxylic acid;
Ethyl 2-[6-(3-ethylurea)-pyridine-3-yl]-4-propellerblades-5-carboxylate;
2-[6-(3-Ethylurea)-pyridine-3-yl]-4-propellerblades-5-carboxylic acid;
5-Dimethylamide, 4-propelled 2-[6-(3-ethylurea)-pyridine-3-yl]-thiazole-4,5-dicarboxylic acid;
Ethyl 2-[6-(3-ethylurea)-pyridine-3-yl]-4-isopropylcarbamate-5-carboxylate;
2-[6-(3-Ethylurea)-pyridi the-3-yl]-4-isopropylcarbamate-5-carboxylic acid;
5-Dimethylamide, 4-ethylamide 2-[6-(3-ethylurea)-pyridine-3-yl]-thiazole-4,5-dicarboxylic acid;
Ethyl 6'-{[(ethylamino)carbonyl]amino}-5 ' -fluorine-3,3':4',3”-terpyridine-5-carboxylate;
6'-{[(Ethylamino)carbonyl]amino}-5 ' -fluorine-3,3':4',3”-terpyridine-5-carboxylic acid;
6'-{[(Ethylamino)carbonyl]amino}-5 ' -fluoro-N-methyl-3,3':4',3”-terpyridine-5-carboxamide;
Methyl 2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-4-[1-(2-methoxyethyl)-1H-imidazol-2-yl]-1,3-thiazole-5-carboxylate;
Methyl 2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-4-(1-methyl-1H-1,2,4-triazole-5-yl)-1,3-thiazole-5-carboxylate;
Ethyl 2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylate;
Ethyl 2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-4-({[(15)-2-methoxy-1-methylethyl]amino}carbonyl)-1,3-thiazole-5-carboxylate;
Methyl 2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-4-(1-methyl-1H-imidazol-2-yl)-1,3-thiazole-5-carboxylate;
Ethyl 4-[(tert-butylamino)carbonyl]-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylate;
Ethyl 6'-{[(ethylamino)carbonyl]amino}-4'-phenyl-3,3'-bipyridine-5-carboxylate;
Ethyl 3-(6-{[(ethylamino)carbonyl]amino}-4-vinylpyridin-3-yl)benzoate;
Methyl 2-(6-{[(ethylamino)carbonyl]amino}-4-vinylpyridin-3-yl)-1,3-thiazole-5-carboxylate;
Ethyl 4-[(butylamino)carbonyl]-2-(6-{[(ethylamino)carbonyl]amino}-4-vinylpyridin-3-yl)-1,3-thiazole-5-carboxylate;
Ethyl 6'-{[(ethylamino)carbon is l]amino}-4'-(4-ethyl-1,3-thiazol-2-yl)-3,3'-bipyridine-5-carboxylate;
Ethyl 3-[6-{[(ethylamino)carbonyl]amino}-4-(4-ethyl-1,3-thiazol-2-yl)pyridine-3-yl]benzoate;
Ethyl 6'-{[(ethylamino)carbonyl]amino}-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxylate;
Methyl 2-{6-{[(ethylamino)carbonyl]amino}-4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]pyridine-3-yl}-1,3-thiazole-5-carboxylate;
Ethyl 6'-{[(ethylamino)carbonyl]amino}-3,3':4',3”-terpyridine-5-carboxylate;
Ethyl 6'-{[(ethylamino)carbonyl]amino}-6 ' -fluorine-3,3':4',3”-terpyridine-5-carboxylate;
Ethyl 6'-{[(isopropylamino)carbonyl]amino}-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxylate;
Ethyl 6'-{[(dt-butylamino)carbonyl]amino}-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxylate;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-4-[1-(2-methoxyethyl)-1H-imidazol-2-yl]-1,3-thiazole-5-carboxylic acid;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-4-(1-methyl-1H-1,2,4-triazole-5-yl)-1,3-thiazole-5-carboxylic acid;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylic acid;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-4-({[(1S)-2-methoxy-1-methylethyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-4-(1-methyl-1H-imidazol-2-yl)-1,3-thiazole-5-carboxylic acid;
4-[(tert-Butylamino)carbonyl]-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylic acid;
6'-{[(Ethylamino)carbonyl]amino}-4'-enyl-3,3'-bipyridine-5-carboxylic acid;
3-(6-{[(Ethylamino)carbonyl]amino}-4-vinylpyridin-3-yl)benzoic acid;
2-(6-{[(Ethylamino)carbonyl]amino}-4-vinylpyridin-3-yl)-1,3-thiazole-5-carboxylic acid;
4-[(Butylamino)carbonyl]-2-(6-{[(ethylamino)carbonyl]amino}-4-vinylpyridin-3-yl)-1,3-thiazole-5-carboxylic acid;
6'-{[(Ethylamino)carbonyl]amino}-4'-(4-ethyl-1,3-thiazol-2-yl)-3,3'-bipyridine-5-carboxylic acid;
3-[6-{[(Ethylamino)carbonyl]amino}-4-(4-ethyl-1,3-thiazol-2-yl)pyridine-3-yl]benzoic acid;
6'-{[(Ethylamino)carbonyl]amino}-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxylic acid;
2-{6-{[(Ethylamino)carbonyl]amino}-4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]pyridine-3-yl}-1,3-thiazole-5-carboxylic acid;
5-[6-(Ethylcarbodiimide)-4-(3-pyridyl)-3-pyridyl]pyridine-3-carboxylic acid;
5-[6-(Ethylcarbodiimide)-4-(6-fluoro-3-pyridyl)-3-pyridyl]pyridine-3-carboxylic acid;
6'-{[(Isopropylamino)carbonyl]amino}-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxylic acid;
6'-{[(dt-butylamino)carbonyl]amino}-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxylic acid;
6'-{[(Ethylamino)carbonyl]amino}-4'-(4-ethyl-1,3-thiazol-2-yl)-N-methyl-3,3'-bipyridine-5-carboxamide;
N4-Butyl-2-(6-{[(ethylamino)-carbonyl]-amino}pyridine-3-yl)-N5-methyl-1,3-thiazole-4,5-dicarboxamide;
N4-Butyl-2-(6-{[(ethylamino)-carbonyl]-amino}pyridine-3-yl)-N5N5-dimethyl-1,3-thiazole-4,5-dicarboxamide is;
N4-(tert-Butyl)-2-(6-{[(ethylamino)-carbonyl]-amino}iridin-3-yl)-N5N5-dimethyl-1,3-thiazole-4,5-dicarboxamide;
N4-(tert-Butyl)-2-(6-{[(ethylamino)-carbonyl]-amino}pyridine-3-yl)-1,3-thiazole-4,5-dicarboxamide;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-N,N-dimethyl-4-(1-methyl-1H-imidazol-2-yl)-1,3-thiazole-5-carboxamide;
2-(6-{[(Ethylamino)-carbonyl]-amino}pyridine-3-yl)-N,N-dimethyl-4-(1-methyl-1H-1,2,4-triazole-3-yl)-1,3-thiazole-5-carboxamide;
6'-{[(Ethylamino)-carbonyl]-amino}-4'-phenyl-3,3'-bipyridine-5-carboxamide;
2-(6-{[(Ethylamino)-carbonyl]-amino}-pyridin-3-yl)-N4-methyl-1,3-thiazole-4,5-dicarboxamide;
2-(6-{[(Ethylamino)-carbonyl]-amino}pyridine-3-yl)-N4-(2-methoxyethyl)-1,3-thiazole-4,5-dicarboxamide;
2-(6-{[(Ethylamino)-carbonyl]-amino}pyridine-3-yl)-N4-[(1S)-2-methoxy-1-methylethyl]-1,3-thiazole-4,5-dicarboxamide;
2-(6-{[(Ethylamino)-carbonyl]-amino}pyridine-3-yl)-N4-[(1S)-2-methoxy-1-methylethyl]-N5N5-dimethyl-1,3-thiazole-4,5-dicarboxamide;
6'-{[(Ethylamino)-carbonyl]-amino}-4'-(4-ethyl-1,3-thiazol-2-yl)-3,3'-bipyridine-5-carboxamide;
6'-{[(Ethylamino)-carbonyl]-amino}-4'-(4-ethyl-1,3-thiazol-2-yl)-N-methyl-3,3'-bipyridine-5-carboxamide;
6'-{[(Ethylamino)-carbonyl]-amino}-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxamide;
6'-{[(Ethylamino)-carbonyl]-amino}-N-methyl-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxamide;
N-(tert-Butyl)-6'-{[(ethylamino)to rbony]-amino}-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxamide;
6'-{[(Ethylamino)-carbonyl]-amino}-N-[(1S)-2-methoxy-1-methylethyl]-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxamide;
N-Cyclopentyl-6'-{[(ethylamino)-carbonyl]-amino}-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxamide;
N-Cyclopropyl-6'-{[(ethylamino)-carbonyl]-amino}-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxamide;
2-{6-{[(Ethylamino)-carbonyl]-amino}-4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]pyridine-3-yl}-N-methyl-1,3-thiazole-5-carboxamide;
6'-{[(Ethylamino)-carbonyl]-amino}-6 ' -fluorine-3,3':4',3”-terpyridine-5-carboxamide;
6'-{[(Isopropylamino)carbonyl]-amino}-N-methyl-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxamide;
6'-{[(dt-butylamino)-carbonyl]-amino}-N-methyl-4'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridine-5-carboxamide;
5-Dimethylamide,4-isopropylamino 6'-(3-ethylurea)-[2,3']bipyridinyl-4,5-dicarboxylic acid;
Ethyl 6'-{[(ethylamino)carbonyl]amino}-4'-(4-phenyl-1,3-thiazol-2-yl)-3,3'-bipyridine-5-carboxylate;
6'-{[(Ethylamino)carbonyl]amino}-4'-(4-phenyl-1,3-thiazol-2-yl)-3,3'-bipyridine-5-carboxylic acid;
6'-{[(Ethylamino)carbonyl]amino}-N-methyl-4'-(4-phenyl-1,3-thiazol-2-yl)-3,3'-bipyridine-5-carboxamide;
Methyl 3-(2-{[(ethylamino)carbonyl]amino}-1,3-thiazol-4-yl)benzoate;
Ethyl 2-(2-{[(ethylamino)carbonyl]amino}pyrimidine-5-yl)-1,3-benzothiazole-7-carboxylate;
Ethyl 5-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)imidazo[1,2-a]pyridine-2-carboxylate;
Ethyl -(2-{[(ethylamino)carbonyl]amino}pyridin-4-yl)benzoate;
Ethyl 4-(2-{[(ethylamino)carbonyl]amino}pyridin-4-yl)benzoate;
Ethyl 6-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-2-methylimidazo[1,2-a]pyridine-3-carboxylate;
Ethyl 4-[(dimethylamino)carbonyl]-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylate;
Ethyl 4'-(4-tert-butyl-1,3-thiazol-2-yl)-6'-{[(ethylamino)carbonyl]amino}-3,3'-bipyridine-5-carboxylate;
3-(2-{[(Ethylamino)carbonyl]amino}-1,3-thiazol-4-yl)benzoic acid;
3-(2-{[(Ethylamino)carbonyl]amino}pyridin-4-yl)benzoic acid;
4-(2-{[(Ethylamino)carbonyl]amino}pyridin-4-yl)benzoic acid;
4'-(4-tert-Butyl-1,3-thiazol-2-yl)-6'-{[(ethylamino)carbonyl]amino}-3,3'-bipyridine-5-carboxylic acid;
[3-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)phenyl]acetic acid;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-4-(1-methyl-1H-1,2,4-triazole-5-yl)-1,3-thiazole-5-carboxylic acid;
6-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-2-methylimidazo [1,2-a]pyridine-3-carboxylic acid;
4-[(dimethylamino)carbonyl]-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxylic acid;
4-[(Butylamino)carbonyl]-2-[6-{[(ethylamino)carbonyl]amino}-4-(4-ethyl-1,3-thiazol-2-yl)pyridine-3-yl]-1,3-thiazole-5-carboxylic acid;
3-(6-{[(Ethylamino)carbonyl]amino}pyridin-2-yl)benzamide;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-4,5-dicarboxamide;
4-Acetyl-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-N,N-dimethyl-1,3-is eazol-5-carboxamide;
4-Acetyl-2-(6-{[(ethylamino)carbonyl]amino}pyridine-3-yl)-1,3-thiazole-5-carboxamide;
6-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-2-methylimidazo [1,2-a]pyridine-3-carboxamide;
3-(6-{[(Ethylamino)carbonyl]amino}pyridin-2-yl)N,N-dimethylbenzamide;
2-(6-{[(Ethylamino)carbonyl]amino}pyridine-3-yl)-4-(1-methyl-1H-1,2,4-triazole-5-yl)-1,3-thiazole-5-carboxamide;
N5-butyl-2-(6-{[ethylamino)carbonyl]amino}pyridine-3-yl)-N4N4-dimethyl-1,3-thiazole-4,5-dicarboxamide;
N5(Strat-Butyl)-2-6-{[ethylamino)carbonyl]amino}pyridine-3-yl)-N4N4-dimethyl-1,3-thiazole-4,5-dicarboxamide;
3-[6-{[(Ethylamino)carbonyl]amino}-4-(4-ethyl-1,3-thiazol-2-yl)pyridine-3-yl]-N,N-dimethylbenzamide;
6'-{[(Ethylamino)carbonyl]amino}-4'-(4-ethyl-1,3-thiazol-2-yl)-N,N-dimethyl-3,3'-bipyridine-5-carboxamide;
N4-Butyl-2-[6-{[(ethylamino)carbonyl]amino}-4-(4-ethyl-1,3-thiazol-2-yl)pyridine-3-yl]-N5N5-dimethyl-1,3-thiazole-4,5-dicarboxamide;
N-Butyl-2-(6-{[(ethylamino)carbonyl]amino}-4-vinylpyridin-3-yl)-1,3-thiazole-4-carboxamide;
4'-(4-tert-Butyl-1,3-thiazol-2-yl)-6'-{[(ethylamino)carbonyl]amino}-N-methyl-3,3'-bipyridine-5-carboxamide; and
6'-{[(Ethylamino)carbonyl]amino}-N4-isopropyl-N5N5-dimethyl-2,3'-bipyridine-4,5-dicarboxamide.

22. Pharmaceutical composition having activity of inhibitors of DNA gyrase and/or topoisomerase IV, comprising the compound according to any one of claims 1 to 21 or FA is matemticas acceptable salt, and pharmaceutically acceptable excipient or carrier.

23. Method of inhibiting bacterial DNA gyrase and/or bacterial topoisomerase IV in a warm-blooded animal that is in need of such treatment, comprising an introduction to the animal an effective amount of a compound according to any one of claims 1 to 21 or its pharmaceutically acceptable salt.

24. A method of treating a bacterial infection in a warm-blooded animal that needs it, including introduction to the animal an effective amount of a compound according to any one of claims 1 to 21 or its pharmaceutically acceptable salt.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: present invention relates to fluorinated compounds of formula , where: D, G and L are independently selected from a group consisting of: CH, C and N, and J and M are independently selected from a group consisting of C and N, under the condition that one of J and M denotes C and the other denotes N, wherein at least two of D, G, M, J and L denote N; X denotes CH2; Y is absent; Z denotes NR1R2; R1 and R2 are independently selected from a group consisting of: hydrogen, C1-C10 alkyl, aryl and heteroaryl, which is associated with aromatic radicals having 6 ring atoms, where 1-2 of these ring atoms are N; each of which can be substituted with one or more halogen atoms; or R1 and R2, together with nitrogen to which they are bonded, form a heterocyclic ring having 5 ring members; R3 is selected from a group consisting of: halogen, C1-C10 alkyl; E denotes aryl which can be substituted with one or more fluoro-substitutes or one or more of the following substitutes: C1-C6 alkyl, QC1-C10 alkyl, QC2-C10 alkenyl, each of which can be substituted with one or more fluoro-substitutes, and where Q denotes O; m denotes a number from 1 to 2; under the condition that: R3 is a fluoro-substitute, or group E includes a fluoro-substitute, or group Z includes a fluoro-substitute, with the condition that E does not denote 4-fluorophenyl or a compound of formula , where D, G and L are independently selected from a group consisting of: CH, C and N, and J and M are independently selected from a group consisting of C and N, under the condition that one of J and M denotes C and the other denotes N, wherein at least two of D, G, M, J and L denote N; X denotes CH2; Y is absent; Z denotes NR1R2; R1 and R2 are independently selected from a group consisting of: hydrogen, C1-C10 alkyl, aryl and heteroaryl, which is associated with aromatic radicals having 6 ring atoms, where 1-2 of these ring atoms are N; each of which can be substituted with one or more of the following substitutes: chlorine, bromine, iodine; or R1 and R2, together with nitrogen to which they are bonded, form a heterocyclic ring having 5 ring members; R3 is selected from a group consisting of: chlorine, bromine, iodine, C1-C10 alkyl; E denotes aryl which can be substituted with one or more chlorine, bromine or iodine atoms, and/or one or more of the following substitutes: C1-C6 alkyl, QC1-C10 alkyl, QC2-C10 alkenyl, each of which can be substituted with one or more substitutes selected from chlorine, bromine, iodine or hydroxy, where Q denotes O, wherein when E denotes phenyl, E does not contain, as a substitute, iodine which is directly bonded to it at position 4; m denotes a number from 1 to 2; wherein at least one of Z, E and R3 includes iodine; under the condition that E does not denote 4-iodophenyl and under the condition that said compound is not a compound of formula (Ia), defined in the following table:

The invention also relates to a pharmaceutical composition based on the compound of formula (I) or (Ia), a diagnosis method, a method of treating said disorders, based on use of the compound of formula (I) or (Ia), and use of the compound of formula (I) or (Ia).

EFFECT: obtaining novel compounds useful in treating disorders in mammals, characterised by anomalous density of peripheral benzodiazepine receptors.

24 cl, 13 dwg, 9 tbl, 23 ex

FIELD: chemistry.

SUBSTANCE: compounds, which have formula I , in which A, B, R1, R1a, R2, R3, R4, R5 R6, R7 and R8 have values given in description and are inhibitors of receptor tyrosinkinases, useful in treatment of diseases, mediated by class 3 and class 5 receptor tyrosinkinases. It has been also discovered that specific compounds of the claimed invention are Pim-1 inhibitors. Also claimed is method of obtaining formula I compound.

EFFECT: increase of compound efficiency.

27 cl, 51 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel derivatives of [1,8]naphthyridine, described by formula I(a), where Z represents -NR41-; A represents phenyl; each R10, R17, R31, R33, R35 and R41 in each case is independently selected from group, consisting of hydrogen, C1-C6alkyl, C1-C6haligenalkyl, phenyl, C3-C6cycloalkyl, -Ls-O-Rs, -Ls-C(O)Rs, -Ls-C(O)ORs and LE-Q-LE-(morpholine); X is selected from group, consisting of bond, -Ls-O-, -Ls-S- and -Ls-C(O)N(Rs)-; R22 is selected from group, consisting of halogen, C1-C6alkyl, phenyl, and phenyl C1-C2alkyl, and, optionally, is substituted with one R26, where R26 in each case is independently selected from group, consisting of halogen, hydroxy, nitro, C1-C6alkyl, -Ls-OSO2Rs; Y is selected from group, consisting of bond, -Ls-O-, -Ls-S(O)-, -Ls-C(O)N(R15) - and -Ls-S-, where R15 represents hydrogen; R50 represents -L1-A1, where A1 is selected from group, consisting of C1-C6alkyl and phenyl and L1 is selected from group, consisting of bond and C1-4alkylene, where A1 is optionally substituted with from one to three R30, and R30 in each case is independently selected from group, consisting of halogen, hydroxy, amino, azido, C1-C6alkyl, -Ls-O-Rs, -Ls-C(O)ORs, -LS-N(RSRS), -Ls-C(=NRs)RS', -Ls-C(O)N(RsRsO, -Ls-N(Rs)C(O)Rs', -LE-Q-LE'- (phenyl or naphthyl) and -LE-Q-LE'-(M5-M6heterocyclyl, which represents pyridine, pyrazine, pyrrolodine, furan, thiophene, piperidine); Ls in each case is independently selected from group, consisting of bond and C1-4alkylene; each RS and Rs' in each case is independently selected from group, consisting of hydrogen, C1-C6alkyl, C3-6alkenyl, C1-6alkoxy, C1-6alkoxyC1-C6alkyl and C1-6alkoxycarbonylC1-C6alkyl; each LE and LE' in each case is independently selected from group, consisting of bond, C1-4alkylene, -C1-4alkylene-NC(O)-C1-4alkylene-; Q in each case is independently selected from group, consisting of bond, -O-, -N(Rs)C(O)-, -C(O)N(Rs)- and -O-SO2-; each R17 and R30 in each case is optionally independently substituted with from one to three substituent(s), selected from group, consisting of halogen and hydroxy; and each heterocyclyl group in -LE-Q-LE'-(M5-M6heterocyclyl) in each case is optionally independently substituted with at least one or two substituents, selected from group, consisting of hydrogen, hydroxy, C1-C6alkyl, C1-6alkoxy, C1-6alkoxycarbonyl, phenyloxy and phenylC1-6alkoxycarbonyl, or to their pharmaceutically acceptable salts. Invention also relates to compounds of formula II(a), pharmaceutical composition based on claimed compounds, application of claimed compounds, method of inhibition of HCV virus replication, method of treating HCV infection.

EFFECT: obtained are novel derivatives, useful in treatment of HCV infection.

FIELD: chemistry.

SUBSTANCE: invention relates to novel derivatives of dihydroquinone and dihydronaphthyridinone of formula (I) or to its pharmaceutically acceptable salts, in which X represents group CR11 or N; Y represents group -C(O)R3, oxazolyl or isoxazolyl; Z represents phenyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, pyridinyl, pyrimidinyl or pyrazolyl, and is substituted with groups R1 and R2; R1 and R2 each independently represents H, halogen, CN group, C1-6alkyl or group -Y1-Y2-Y3-R8, or R1 and R2 together form group -O(CH2)nO-, where n represents 1 or 2; Y1 represents group -O-, -C(O)-, -C(O)O-, -C(O)NR9-, -NR9C(O), -S-, -SO2- or bond; Y2 represents heterocycloalkylene, C1-6alkylene or bond, where heterocycloalkylene stands for cycloalkylene group, in which one, two carbon atoms are substituted with heteroatoms O or N, where heterocycloalkylene group also contains, at least, two carbon atoms and cycloalkylene represents ; Y3 represents group -O-, -C(O)-, -C(O)O-, -C(O)NR9-, -NR9C(O)-, -SO2- or bond; R8 represents H, C1-6alkyl, C1-6alkoxy, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, or group -NR9R10, where R8, different from H, is optionally substituted with C1-6alkyl, halogen, group -CF3 or group -OH; R9 and R10 each independently represents H or C1-6alkyl; R3 represents OH, C1-6alkyl, C1-6alkoxy, (C1-6alkoxy)-C1-6alkoxy; R4 represents C1-6alkyl, phenyl, cyclopropyl, cyclobutyl, cyclobutyl, cyclohexyl, tetrahydropyranyl or tetrahydrothiophene 1,1 -dioxide, and is optionally substituted with C1-6alkyl, hydroxyl group, C1-6alkoxy, halogen, nitro group, amino group, cyano group or halo-lower alkyl; R5 and R6 each independently represents H, halogen, C1-6alkyl, group -CF3, C1-6alkoxy; R7 represents H; R11 represents H. Invention also re4lates to pharmaceutical composition based on formula (I) compound.

EFFECT: obtained are novel dihydroquinone and dihydronaphthyridinone derivatives, useful for treatment of disease mediated by JNK kinase.

9 cl, 4 tbl, 38 ex

FIELD: medicine.

SUBSTANCE: invention refers to an agent for activation of lipoprotein lipase containing a benzene derivative of general formula (1) which is used for preventing and treating hyperlipidemia and obesity. The invention also refers to the benzene derivatives of general formula (1a).

EFFECT: composition improvement.

8 cl, 6 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of general formula 1:

wherein Q, X1, X2, Y, Z, R1, R2, R3, R3', R4, R4', R5, R6, R6' have the values specified in the description.

EFFECT: compounds are the IAP inhibitors which can be used as therapeutic agents for malignant diseases.

13 cl, 20 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new bicyclic heterocyclic derivatives of general formula wherein radicals and symbols are specified in the patent claim. Said compounds are FGFR receptor (fibroblast growth factor receptor) inhibitors. The invention also refers to a method for preparing a preferential group of compounds of formula (I), to a pharmaceutical composition containing said compounds, and to the use of said compounds for treating diseases, e.g. cancer.

EFFECT: preparing the new bicyclic heterocyclic derivatives.

22 cl, 16 tbl, 422 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel bicyclic heterocyclic derivatives, which are compounds of formula where values of X1-X5, A, B, R1, R2, q are given in claim 1, as well as pharmaceutical compositions containing said compounds, and use of said compounds to treat cancer.

EFFECT: high efficiency of treatment.

22 cl, 43 ex

FIELD: chemistry.

SUBSTANCE: invention relates to 9-(quinonyl-2)-2-n-ethoxyphenylethyl-4,5,6,7,8,9,10,11-octahydropyrido[1,2-a] pyrazine-1,4-dione of formula I or pharmaceutically acceptable complex derivatives thereof. The invention also relates to use of the compound of formula I.

EFFECT: novel derivative which can be used as an antiulcer agent is obtained.

4 cl, 1 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to substituted sulphamide derivatives of formula I: , in which n, m, R1, R2a-c, R3, R4, R5 and R6 are as described in claim 1, in form of a racemate, enantiomers, diastereomers, mixtures of enantiomers or diastereomers or a separate enantiomer or diastereomer, bases and/or salts of physiologically compatible acids. The invention also relates to a method of producing said compounds, a medicinal agent having antagonist action on bradykinin receptor 1 (B1R), containing such compounds, use of such compounds to produce medicinal agents, as well as sulphamide-substituted derivatives selected from a group of compounds given in claim 8.

EFFECT: providing novel compounds which are suitable as pharmacologically active substances in medicinal agents for treating disorders or diseases which are at least partially transmitted through B1R receptors.

13 cl, 581 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to dihydropyrazolone derivatives or of formula (I), where R1 denotes a heteroaryl group of formulae given below, where * denotes the linkage point with the dihydropyrazolone ring, A in each individual occurrence denotes C-R4 or N, wherein at most two ring members A represent N at the same time, E denotes O or S, R2, R3 and R4 are as defined in the claim. The invention also relates to a method of producing said compounds.

EFFECT: compounds of formula (I) inhibit HIF-propylhydroxylase activity and can be used to treat and/or prevent diseases, as well as for producing medicaments for treating and/or preventing diseases, particularly cardiovascular and haematologic diseases, kidney diseases, and for promoting the healing of wounds.

10 cl, 10 tbl, 178 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel substituted pyrimidine derivatives having PGDS inhibiting properties. In formula (I): (I), R1 denotes phenyl or a 5- or 6-member heteroaryl containing 1-3 heteroatoms selected from N, O and S, each optionally having one or more of the following independent substitutes: halogen, (C1-C6)-alkyl, or (C1-C4)-haloalkyl; R2 denotes hydrogen or (C1-C6)-alkyl, which is optionally substituted with one or more halogens; R3 denotes hydrogen, (C1-C6)-alkyl or phenyl; R4 denotes C6-cycloalkyl, phenyl, a 6-member heterocyclyl containing one N heteroatom, a 6-member heteroaryl containing one N heteroatom, -C(=O)-NY1Y2, -C(=S)-NY1Y2, or -C(=O)-R5, where the phenyl, 6-member heteroaryl or 6-member heterocyclyl group optionally has one or more independent substitutes R6, or R3 and R4 together with a nitrogen atom with which they are bonded form a 5- or 6-member heterocyclyl containing one or two heteroatoms selected from N, O and S, a 6-member heterocyclenyl containing two or three N heteroatoms, a 5-member monocyclic or 9-member bicyclic heteroaryl containing one to three N heteroatoms, phenylheterocyclyl, where the heterocyclyl is 5- or 6-membered and contains one or two heteroatoms selected from N and O, each optionally having one or more independent substitutes R6. Values of R5, R6, Y1, Y2 are given in the claim. The invention also relates to a pharmaceutical composition containing said compounds.

EFFECT: improved method.

15 cl, 227 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula (I) , where R1 denotes an ethoxy group; R2 denotes hydrogen; R3 denotes a cyano group; R4 denotes hydrogen; R5 denotes hydrogen, a methoxy group or an ethoxy group; R6 denotes hydrogen or a methoxy group; R7 denotes hydrogen, methyl, ethyl, n-propyl or isopropyl; X1 denotes -NH-; X2 denotes N or CH; X3 denotes N or CH; where X2 and X3 do not denote N at the same time; and pharmaceutically acceptable salts and tautomeric forms thereof. The invention also relates to a medicinal agent for treating and/or preventing a vasopressin-dependent disease, which contains the compound given in claim 1, use of the compound of formula I to prevent and/or treat vasopressin-dependent diseases, as well as a method of treating and/or preventing said diseases.

EFFECT: novel compounds which can be useful in treating vasopressing-dependent diseases are described.

22 cl, 90 ex, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: it has been confirmed that the new azolcarboxamide compound or its pharmaceutically acceptable salt wherein a thiazole ring or an oxazole ring is bound to a benzene ring, a pyridine ring, a pyridazine ring, a thiophen ring, a pyrazole ring or a pyrrol ring through carboxamide or its ring possess high activity of receptor trkA inhibition; it has been found that they may be used as a therapeutic and/or preventive agent which is different in the fact concerning the effectiveness and safety for repeated urination, frequent micturate urge and urine incontinence associated with various urogenital diseases, including higher bladder activity, various lower bladder diseases accompanied with urogenital pain, such as interstitial cystitis, chronic prostatitis and others, and various diseases accompanied by pain; thereby the present invention has been created.

EFFECT: provided therapeutic and/or preventive agent for repeated urination, frequent micturate urge and urine incontinence associated with various urogenital diseases, including higher bladder activity, various lower bladder diseases accompanied with urogenital pain, such as interstitial cystitis, chronic prostatitis and others, and various diseases accompanied by pain on the basis of excellent inhibitory action on the receptor trkA.

24 cl, 1195 ex, 215 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel 2-aza-bicyclo[3,1,0]hexane derivatives of formula (I), where A, B, n and R1 are defined in the description, and to use of such compounds or pharmaceutically acceptable salts of such compounds as medicinal agents, particularly as orexin receptor antagonists. The present invention also describes use of compounds of general formula (I) to produce a medicinal agent for preventing or treating insomnia.

EFFECT: improved method.

11 cl, 279 ex, 1 tbl, 10 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula I , and pharmaceutically acceptable salts thereof, where L denotes O, S, or CH2; Y denotes N or CH; Z denotes CR3; G denotes CH; R1 denotes a heteroaryl ring of formula , where D1 denotes S, O; D2 denotes N or CR12; D3 denotes CR12; R2 denotes (C6-C10)-aryl; 5-9-member mono- or bicyclic heteroaryl with 1 or 2 heteroatoms independently selected from N or S; a saturated or partially saturated (C3-C7)-cycloalkyl; or a saturated 5-6-member heteocyclyl with 1 heteroatom selected from N, where said aryl, heteroaryl, cycloalkyl and heterocyclyl are optionally substituted with one or two groups independently selected from (C1-C6)-alkyl, F, Cl, Br, CF3, CN, NO2, OR6, C(-O)R6, C(=O)OR6, C(=O)NR6R7, saturated 6-member heterocyclyl with 2 heteroatoms independently selected from N or O, and S(O)2R6, and where said alkyl is optionally substituted with one -OR8 group; R3 denotes H; (C1-C6)-alkyl; (C2-C6)-alkenyl; Cl; Br; OR6; SR6; phenyl; or a 6-member heteroaryl with 1 heteroatom selected from N, where said alkyl and alkenyl are optionally substituted with one group selected from C(=O)OR8, -OR8, -NR8R9; or a saturated 6-member heterocyclyl with 1 heteroatom selected from N or O.

EFFECT: disclosed compounds are used in treating and preventing diseases mediated by insufficient level of glucokinase activity, such as sugar diabetes.

16 cl, 479 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing compounds of formula I The method is realised via cyclisation of a compound of formula (IV) with an intermediate compound Int4 at room temperature to obtain a compound of formula (III), reducing the nitro group in the compound of formula (III) to obtain a compound of formula (II). Further, by bonding the compound of formula (II) to a compound of formula Int5 in an aprotic solvent, a compound of formula (I) is obtained (structural formulae of compounds (II), (III), (IV), Int4, Int5 are given in the claim).

EFFECT: improved method of producing compounds of formula (I).

25 cl, 3 dwg, 4 ex

Indole derivative // 2454415

FIELD: medicine, pharmaceutics.

SUBSTANCE: object of the present invention is preparing a glucokinase activator effective as a pharmaceutical agent, such as an agent for preventing or treating diabetes, obesity and similar. The present invention presents the glucokinase activator containing a compound presented by formula :

wherein R1 represents hydrogen atom or halogen atom; R2 represents a group presented by formula or wherein each symbol is such as specified in the description, or its pharmaceutically acceptable salt.

EFFECT: developing the agent for preventing or treating diabetes, obesity.

16 cl, 536 ex, 1 tbl, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)-piperidin-4-ylidene)methyl)benzamide, and/or their mixture, as well as to applying it in a pharmaceutical composition, a method of treating to be applied for treating pain, anxiety, depression, worried depression or Parkinson's disease. Also, the invention refers to methods for preparing N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)-piperidin-4-ylidene)methyl)benzamide and its intermediate compounds. .

EFFECT: developing the method of treating to be applied for treating pain, anxiety, depression, worried depression or Parkinson's disease.

12 cl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula 1 and salts thereof, fungicidal compositions based on said compounds, a plant disease control method using compounds of formula , as well as intermediate compounds of formulae and . Values of radicals are given in the description.

EFFECT: high efficiency of the compounds.

14 cl, 20 dwg, 284 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present patent claim discloses sulphonyl-substituted compounds of formula QUIN which are used for the purpose of a method for producing a macrocyclic compound of formula (I)

EFFECT: compounds of formula (I) are effective active agents for treating Hepatitis C viral (HCV) infection.

8 cl, 1 ex

Up!